• Source : Press Release
  • Date : 2021-05-03
  • Companies : Merck KGaA

MoonLake Immunotherapeutics AG Was Founded in 2021, Backed by a Series A Financing

MoonLake Immunotherapeutics AG was founded in 2021, backed by a Series A financing led by BVF Partners LP. Other investors include Merck KGaA, Darmstadt, Germany. The Company has been founded by a highly expert executive leadership team with decades of experience in immunology, including discovery, clinical development, regulatory affairs, product launch, commercialization & business development.

Sourced from the press release with the same date: "MoonLake Immunotherapeutics in-licenses potentially best-in-class Tri-specific Nanobody®,[6] Sonelokimab (M1095/ALX 0761) from Merck KGaA, Darmstadt, Germany, with goal of transforming treatment of inflammatory diseases driven by IL-17A and F"